Financial Performance - The company's revenue increased by 27.6% to RMB 4,076.7 million for the year ended December 31, 2023, compared to RMB 3,195.6 million for the previous year[2]. - Net profit rose by 42.1% to RMB 684.9 million for the year ended December 31, 2023, up from RMB 481.9 million in the prior year[2]. - Basic earnings per share increased by 40.3% to RMB 1.08 for the year ended December 31, 2023, compared to RMB 0.77 for the previous year[2]. - The adjusted net profit under non-IFRS measures was RMB 713.4 million, a 17.5% increase from RMB 607.0 million in the previous year[9]. - The company's total revenue for the year ended December 31, 2023, was RMB 4,076.7 million, a 27.6% increase from RMB 3,195.6 million in 2022[17]. - Revenue from the oncology business was RMB 1,778.4 million, accounting for 43.6% of total revenue, while non-oncology business revenue was RMB 2,298.2 million, accounting for 56.4%[17]. - The gross profit from the core hospital business reached RMB 1,179.2 million, a 26.8% increase year-on-year, with a 39.3% increase when excluding the one-time impact of nucleic acid testing[17]. - The gross profit increased by 25.1% from RMB 1,028.6 million to RMB 1,286.3 million, with a 36.0% year-on-year growth after excluding the one-time impact of nucleic acid testing[58]. - The net profit attributable to the owners of the company was RMB 682,928,000, compared to RMB 476,784,000 in the previous year, marking a significant increase of 43.2%[130]. Hospital Operations - The hospital business revenue reached RMB 3,890.3 million, a 28.5% increase, with inpatient services revenue growing by 31.6% to RMB 2,538.9 million[13]. - Outpatient services revenue was RMB 1,351.4 million, reflecting a 23.1% increase, with a 43.2% growth when excluding one-time impacts from nucleic acid testing[13]. - The company completed 83,770 surgeries, a 34.6% increase from the previous year, with a higher proportion of complex and interventional surgeries[13]. - Revenue from hospital operations accounted for 95.4% of total revenue, rising by 28.5% from RMB 3,027.3 million to RMB 3,890.3 million, with a 35.4% year-on-year growth after excluding the one-time impact of nucleic acid testing[55]. Acquisitions and Expansion - The group has expanded its medical service network with three new hospitals under construction: Dezhou Haijia Hospital (1,000 beds), Wuxi Haijia Hospital (800-1,000 beds), and Changshu Haijia Hospital (800-1,200 beds) with completion expected in 2024 and 2025[29][30]. - The group has acquired 89.2% of Yixing Haijia Hospital, which has the potential to upgrade to a tertiary hospital and will enhance the group's tumor medical service revenue and market share in the Yangtze River Delta region[33][35]. - The acquisition of Chang'an Hospital, which has an average of 630,000 patient visits from 2020 to 2022 and 1,000 registered beds, will further expand the group's medical service network in Northwest China[36]. - The group has announced the acquisition of Qufu Chengdong Hospital, which will improve operational efficiency and diagnostic capabilities through standardized management practices[37]. - The company aims to expand its business scale through new hospital projects and acquisitions of quality hospital targets to meet the growing demand for oncology services[51]. Employee and Talent Management - The number of medical professionals increased to 7,483, up by 2,356 from the previous year, including 1,188 senior technical personnel, an increase of 380[26]. - The group continues to enhance its talent acquisition and training mechanisms, focusing on building a competitive workforce in the healthcare sector[24]. - Employee compensation expenses totaled RMB 1,335.9 million for the year ending December 31, 2023, an increase from RMB 1,049.8 million for the previous year[107]. Financial Position and Cash Flow - Cash and cash equivalents as of December 31, 2023, totaled RMB 549.7 million, with structured deposits and financial products amounting to RMB 206.2 million[70]. - Net cash inflow from operating activities increased by 14.2% to RMB 782.8 million for the year ended December 31, 2023, due to an overall increase in revenue[71]. - Net cash used in investing activities surged by 669.6% to RMB 2,863.5 million for the year ended December 31, 2023, primarily due to increased payments for acquisitions of subsidiaries[72]. - The total assets of the company increased by 48.2% from RMB 7,241.9 million as of December 31, 2022, to RMB 10,734.6 million as of December 31, 2023[77]. - The total liabilities rose by 94.6% from RMB 2,301.9 million as of December 31, 2022, to RMB 4,479.7 million as of December 31, 2023, primarily due to new hospital acquisitions[77]. Corporate Governance and ESG Initiatives - The company has established a robust corporate governance structure to enhance accountability and protect shareholder interests[118]. - The group emphasizes the protection of stakeholders' rights, including patients, shareholders, and employees, while continuously improving its governance and operational efficiency[40]. - The company is committed to enhancing its ESG initiatives, focusing on environmental management and corporate governance to protect stakeholder interests[51]. - The group is committed to improving its environmental performance by setting targets for greenhouse gas emissions, water resource usage, and energy consumption by 2030[42]. Community Engagement and Brand Image - The group actively participates in community health initiatives, including free blood donation and cancer screening programs, enhancing its brand image and social influence[40]. - The company established multiple tumor screening centers and conducted health seminars, enhancing early detection and treatment capabilities for cancer patients[21]. Stock Options and Shareholder Matters - The company has adopted a stock option plan on October 15, 2021, allowing the issuance of up to 18,540,000 shares, representing 3% of the total issued shares as of that date[108]. - The board has decided not to declare any final dividend for the year ending December 31, 2023[96]. - The total fair value of stock options granted to employees during the reporting period was HKD 153,656,830, with 6,738,000 options granted[113].
海吉亚医疗(06078) - 2023 - 年度业绩